Payment overview · 2025
General Payments
$109.65
5 reported records · 4 companies
Healthcare provider profile · identity verified
William Frederick Shudde, MD
Allopathic & Osteopathic Physicians|Family Medicine · ABILENE, TX · NPI 1780756981
Verified facts
What the public records show
CMS Open Payments records show William Frederick Shudde, MD received $109.65 in general payments during 2025 across 5 reported records.
Exact Sciences Corporation accounted for 43.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.04 | 43.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $25.43 | 23.2% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $18.14 | 16.5% | 1 | 2025 |
| SI-BONE, INC. | Unresolved — no canonical attribution shown | $18.04 | 16.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $109.65 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.04 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $25.43 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $18.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 326 | 175 |
| Levothyroxine Sodium | Levothyroxine Sodium | 314 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 64 |
| Atorvastatin Calcium | Atorvastatin Calcium | 222 | 63 |
| Amlodipine Besylate | Amlodipine Besylate | 180 | 55 |
| Metoprolol Succinate | Metoprolol Succinate | 180 | 48 |
| Gabapentin | Gabapentin | 148 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 145 | 43 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 129 | 37 |
| Potassium Chloride | Potassium Chloride | 117 | 30 |
| Alprazolam | Alprazolam | 113 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 29 |
| Simvastatin | Simvastatin | 105 | 31 |
| Furosemide | Furosemide | 101 | 34 |
| Lisinopril | Lisinopril | 100 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 97 | 46 |
| Cefuroxime | Cefuroxime Axetil | 90 | 71 |
| Escitalopram Oxalate | Escitalopram Oxalate | 87 | 22 |
| Montelukast Sodium | Montelukast Sodium | 87 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 86 | 22 |
| Metformin Hcl | Metformin Hcl | 85 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 83 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 77 | 31 |
| Ozempic | Semaglutide | 77 | 15 |
| Eliquis | Apixaban | 74 | 20 |
| Losartan Potassium | Losartan Potassium | 71 | 22 |
| Trazodone Hcl | Trazodone Hcl | 70 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 68 | 16 |
| Temazepam | Temazepam | 67 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 64 | 18 |
| Metoprolol Tartrate | Metoprolol Tartrate | 63 | 17 |
| Memantine Hcl | Memantine Hcl | 61 | 14 |
| Sertraline Hcl | Sertraline Hcl | 57 | 16 |
| Celecoxib | Celecoxib | 56 | 16 |
| Carvedilol | Carvedilol | 54 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 54 | 38 |
| Quetiapine Fumarate | Quetiapine Fumarate | 53 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 49 | 16 |
| Amitriptyline Hcl | Amitriptyline Hcl | 48 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 16 |
| Finasteride | Finasteride | 46 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 36 |
| Clonazepam | Clonazepam | 44 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 43 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 43 | suppressed |
| Bupropion Xl | Bupropion Hcl | 42 | suppressed |
| Omeprazole | Omeprazole | 42 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | suppressed |
| Methocarbamol | Methocarbamol | 40 | 27 |
| Atenolol | Atenolol | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 39 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 38 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 38 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | 12 |
| Allopurinol | Allopurinol | 37 | suppressed |
| Jardiance | Empagliflozin | 36 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 35 | 14 |
| Estradiol | Estradiol | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 32 | 12 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 26 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Mounjaro | Tirzepatide | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Meloxicam | Meloxicam | 18 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Cephalexin | Cephalexin | 17 | 16 |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Tradjenta | Linagliptin | 17 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 16 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | 11 |
| Diltiazem 24hr Er (Xr) | Diltiazem Hcl | 14 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 12 | suppressed |
| Azithromycin | Azithromycin | 12 | 11 |
| Bromocriptine Mesylate | Bromocriptine Mesylate | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Famotidine | Famotidine | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Digoxin | Digoxin | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Lorazepam | Lorazepam | 11 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $109.65 · 5 records | Exact Sciences Corporation | Cologuard Collection Kit, FREESTYLE LIBRE, Fluad, Flucelvax | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error